Refinement of Risk-Stratification of Cytogenetically Normal Acute Myeloid Leukemia Adult Patients by MN1 Expression.


Journal

Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625

Informations de publication

Date de publication:
01 Jul 2024
Historique:
received: 23 10 2023
medline: 28 7 2024
pubmed: 28 7 2024
entrez: 28 7 2024
Statut: epublish

Résumé

Acute myeloid leukemia with normal cytogenetics (CN-AML) represents a heterogeneous group having diverse genetic mutations. Understanding the significance of each of these mutations is necessary. In this study, we evaluated the prognostic role of MN1 expression in adult CN-AML patients. One hundred and sixty-three de-novo adult AML patients were evaluated for MN1 expression by real-time PCR. MN1 expression was correlated with the clinical characteristics of the patients and their outcomes. Higher MN1 expression was associated with NPM1 wild-type (p<0.0001), CD34 positivity (p=0.006), and lower clinical remission rate (p=0.027). FLT3-ITD and CEBPA mutations had no association with MN1 expression. On survival analysis, a high MN1 expression was associated with poor event-free survival (Hazard Ratio 2.47, 95% Confidence Interval: 1.42-4.3; p<0.0001) and overall survival (Hazard Ratio 4.18, 95% Confidence Interval: 2.17-8.08; p<0.0001). On multivariate analysis, the MN1 copy number emerged as an independent predictor of EFS (p<0.0001) and OS (p<0.0001). MN1 expression is an independent predictor of outcome in CN-AML.

Identifiants

pubmed: 39068559
doi: 10.31557/APJCP.2024.25.7.2283
pii:
doi:

Substances chimiques

MN1 protein, human 0
Nucleophosmin 117896-08-9
Tumor Suppressor Proteins 0
NPM1 protein, human 0
Trans-Activators 0
Biomarkers, Tumor 0
CCAAT-Enhancer-Binding Proteins 0
fms-Like Tyrosine Kinase 3 EC 2.7.10.1
Nuclear Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2283-2289

Auteurs

Aparna Ningombam (A)

Laboratory Medicine, JPNATC, AIIMS, New Delhi, India.

Deepak Verma (D)

Laboratory Oncology, Dr. BRAICH, AIIMS, New Delhi, India.

Rajive Kumar (R)

Laboratory Oncology, Dr. BRAICH, AIIMS, New Delhi, India.

Jay Singh (J)

Laboratory Oncology, Dr. BRAICH, AIIMS, New Delhi, India.

M Shadab Ali (MS)

Pulmonary Medicine, AIIMS, New Delhi, India.

Avanish Kumar Pandey (AK)

Laboratory Oncology, Dr. BRAICH, AIIMS, New Delhi, India.

Inder Singh (I)

Neurology, AIIMS, New Delhi, India.

Sameer Bakhshi (S)

Medical Oncology, AIIMS, New Delhi, India.

Atul Sharma (A)

Medical Oncology, AIIMS, New Delhi, India.

Deepam Pushpam (D)

Medical Oncology, AIIMS, New Delhi, India.

Jayanth Kumar Palanichamy (JK)

Medical Oncology, AIIMS, New Delhi, India.

Pranay Tanwar (P)

Laboratory Oncology, Dr. BRAICH, AIIMS, New Delhi, India.

Amar Ranjan Singh (A)

Laboratory Oncology, Dr. BRAICH, AIIMS, New Delhi, India.

Anita Chopra (A)

Laboratory Oncology, Dr. BRAICH, AIIMS, New Delhi, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH